Farmas USA

CLSN

Datos expuestos y comentados entre pares en la conferencia de oncología de NY con buenos resultados

The data from the HEAT Study post-hoc analysis presented by Professors Lencioni and Poon demonstrate that ThermoDox markedly improves PFS and OS in patients with a single lesion if their lesions undergo RFA for 45 minutes or more. These findings apply to HCC lesion regardless of size and represent a subgroup of approximately 300 patients or 42% of the patients in the HEAT Study. The post-hoc analysis completed by the Company to-date indicates that there may be a large patient cohort that benefited from RFA plus ThermoDox regardless of lesion size.

http://investor.celsion.com/releaseDetail.cfm?ReleaseID=765703

Presentación, aquí:
http://files.shareholder.com/downloads/CLN/2363160950x0x665064/aa984646-98ff-49b0-aa7b-95d79826125a/Lencioni%20HEAT%20WCIO%202013.pdf

y +11% en premarket
CLSN

ARNA

Imparable. Que igual no es para tanto y hay altibajos que deberá tener en cuenta el inversor inteligente.

That would indicate a drug that is not yet blockbuster ($1 billion in 1 year), but past a level that would make Belviq a viable and meaningful contributor to the bottom line

For savvy traders, there will be a lot of action to consider.

http://seekingalpha.com/article/1442611-arena-outlines-belviq-launch-and-goals?source=email_rt_article_title

XNPT comienza en breve a distribuir su droga Horizant (junio)

http://finance.yahoo.com/news/xenoport-provides-availability-horizant-123000614.html

Farmacoooooooooooooooo. Al que vuelva a decir "droga" le pego.

He triunfado. Metí largo ALK y corto SGEN y ya me he salido. 200 pavos en media hora.

jajaja si no es por el idioma es que me hace más gracia llamarlo así

me fui de ARNA aburrido asi que lo mas seguro es que suba. sigo con CLSN que le cuesta superar ese euro y ZLCS que.....en fin.